FRANK DELAND: Open Payments
NPI 1851451793 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,509 in 85 payments from 16 companies in 2025. Trend: 2023 $1,472 · 2024 $1,518 · 2025 $1,509
Food & beverage: $1,509
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $306 |
| Otsuka America Pharmaceutical, Inc. | 9 | $166 |
| Bausch Health US, LLC | 11 | $146 |
| Alkermes, Inc. | 7 | $139 |
| Noven Therapeutics, LLC | 6 | $108 |
| Janssen Pharmaceuticals, Inc | 5 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $90 |
| Vanda Pharmaceuticals Inc. | 3 | $86 |
| Lundbeck LLC | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $64 |
Products named: VRAYLAR, REXULTI, APLENZIN, LYBALVI, Xelstrym, CAPLYTA, HETLIOZ, SPRAVATO.
Industry payments across KY — which companies pay providers there.
